Mathai Mammen's Insider Trades & SAST Disclosures
Mathai Mammen's most recent trade in 10x Genomics Inc - Ordinary Shares - Class A was a trade of 8,649 Class A Common Stock done . Disclosure was reported to the exchange on June 11, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mathai Mammen.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| 10x Genomics Inc - Ordinar... | Mathai Mammen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 8,649 | 180,259 (0%) | 0% | 0 | Class A Common Stock | |
| 10x Genomics Inc - Ordinar... | Mathai Mammen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 4,661 | 4,661 | - | - | Stock Option (right to buy) | |
| 10x Genomics Inc - Ordinar... | Mathai Mammen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 1,865 | 171,610 (0%) | 0% | 0 | Class A Common Stock | |
| 10x Genomics Inc - Ordinar... | Mathai Mammen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2023 | 200,000 | 0 | - | - | Stock Option (right to buy) | |
| 10x Genomics Inc - Ordinar... | Mathai Mammen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. | 11 May 2023 | 200,000 | 202,745 (0%) | 0% | 1.2 | 232,000 | Class A Common Stock |
| 10x Genomics Inc - Ordinar... | Mathai Mammen | Director | Sale of securities on an exchange or to another person at price $ 52.82 per share. | 11 May 2023 | 33,000 | 169,745 (0%) | 0% | 52.8 | 1,743,086 | Class A Common Stock |
| 10x Genomics Inc - Ordinar... | Mathai Mammen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 5,300 | 5,300 | - | - | Stock Option (right to buy) | |
| 10x Genomics Inc - Ordinar... | Mathai Mammen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 2,120 | 2,745 (0%) | 0% | 0 | Class A Common Stock | |
| Johnson & Johnson | Mathai Mammen | EVP, Pharm, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 38,736 | 38,736 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Mathai Mammen | EVP, Pharm, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 7,740 | 737 | - | - | Performance Share Units | |
| Johnson & Johnson | Mathai Mammen | EVP, Pharm, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 7,740 | 45,300 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Mathai Mammen | EVP, Pharm, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 7,418 | 39,895 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Mathai Mammen | EVP, Pharm, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 7,418 | 0 | - | - | Restricted Share Units | |
| Johnson & Johnson | Mathai Mammen | EVP, Pharm, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 3,922 | 3,922 | - | - | Restricted Share Units | |
| Johnson & Johnson | Mathai Mammen | EVP, Pharm, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 165.89 per share. | 14 Feb 2022 | 3,366 | 41,934 (0%) | 0% | 165.9 | 558,386 | Common Stock |
| Johnson & Johnson | Mathai Mammen | EVP, Pharm, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 168.85 per share. | 14 Feb 2022 | 2,335 | 37,560 (0%) | 0% | 168.9 | 394,265 | Common Stock |
| 10x Genomics Inc - Ordinar... | Mathai Mammen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2021 | 1,563 | 1,563 | - | - | Stock Option (right to buy) | |
| 10x Genomics Inc - Ordinar... | Mathai Mammen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2021 | 625 | 625 (0%) | 0% | 0 | Class A Common Stock | |
| 10x Genomics Inc - Ordinar... | Mathai Mammen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2020 | 4,432 | 4,432 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges